DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia

Leuk Res. 2011 Aug;35(8):1087-92. doi: 10.1016/j.leukres.2011.01.010. Epub 2011 Feb 9.

Abstract

Drug resistance is a challenge in treatment of acute leukemia. To investigate novel protein changes involved in resistance, protein expression profiles between leukemia cell line HL-60 and adriamycin-resistant HL-60 (HL-60/ADR) were compared based on a proteomic approach-2D-DIGE followed by MALDI-TOF/MS. 13 protein spots were identified as up-regulated and 3 down-regulated in HL-60/ADR. Nucleophosmin/B23 (NPM B23) and nucleolin C23 (C23) were selected and verified by western blot, which showed an obvious up-regulation in leukemia cells, especially in 3 resistant leukemia cell lines and in relapsed/refractory patients. To a conclusion, B23 and C23 may be involved in drug resistance and be useful in assessing the prognosis of leukemia.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Blotting, Western
  • Case-Control Studies
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Leukemia / metabolism*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / metabolism*
  • Nuclear Proteins / metabolism*
  • Nucleophosmin
  • Phosphoproteins / metabolism*
  • Proteomics*
  • Survival Rate
  • Treatment Outcome
  • Tumor Cells, Cultured
  • Two-Dimensional Difference Gel Electrophoresis
  • Up-Regulation
  • Young Adult

Substances

  • NPM1 protein, human
  • Nuclear Proteins
  • Phosphoproteins
  • phosphoprotein C23
  • Nucleophosmin